136 related articles for article (PubMed ID: 34815260)
1. Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis.
Tadrous M; Daniels B; Pearson SA; Gomes T
CMAJ Open; 2021; 9(4):E1048-E1054. PubMed ID: 34815260
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.
Tadrous M; Martins D; Mamdani MM; Gomes T
CMAJ Open; 2020; 8(2):E297-E303. PubMed ID: 32345708
[TBL] [Abstract][Full Text] [Related]
3. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
McLeod L; Bereza BG; Shim M; Grootendorst P
Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
[TBL] [Abstract][Full Text] [Related]
4. How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
Allin S; Law MR; Laporte A
Health Policy; 2013 May; 110(2-3):147-55. PubMed ID: 23522381
[TBL] [Abstract][Full Text] [Related]
5. Estimated cost of universal public coverage of prescription drugs in Canada.
Morgan SG; Law M; Daw JR; Abraham L; Martin D
CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims database study.
Wammes JJG; Tanke M; Jonkers W; Westert GP; Van der Wees P; Jeurissen PP
BMJ Open; 2017 Nov; 7(11):e017775. PubMed ID: 29133323
[TBL] [Abstract][Full Text] [Related]
7. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
8. Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.
Tadrous M; Greaves S; Martins D; Mamdani MM; Juurlink DN; Gomes T
CMAJ Open; 2018 Mar; 6(1):E132-E138. PubMed ID: 29581101
[TBL] [Abstract][Full Text] [Related]
9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
10. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
Morgan SG; Li W; Yau B; Persaud N
CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
[TBL] [Abstract][Full Text] [Related]
11. Prescription Drug Price Paradox: Cost Analysis of Canadian Online Pharmacies versus US Medicare Beneficiaries for the Top 100 Drugs.
Kim SH; Ryu YJ; Cho NE; Kim AE; Chang J
Clin Drug Investig; 2017 Oct; 37(10):957-963. PubMed ID: 28735450
[TBL] [Abstract][Full Text] [Related]
12. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015-2021: a repeated cross-sectional study.
Gaudette É; Rizzardo S; Zhang Y; Pothier KR; Tadrous M
BMJ Open; 2024 Mar; 14(3):e082568. PubMed ID: 38485176
[TBL] [Abstract][Full Text] [Related]
15. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.
Morgan SG; Lee A
BMJ Open; 2017 Jan; 7(1):e014287. PubMed ID: 28143838
[TBL] [Abstract][Full Text] [Related]
16. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
Tseng CW; Brook RH; Keeler E; Steers WN; Mangione CM
JAMA; 2004 Aug; 292(8):952-60. PubMed ID: 15328327
[TBL] [Abstract][Full Text] [Related]
17. Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study.
Tadrous M; Brahmania M; Martins D; Knowles S; Janssen HLA; Mamdani MM; Juurlink DN; Gomes T
J Manag Care Spec Pharm; 2018 May; 24(5):464-468. PubMed ID: 29694284
[TBL] [Abstract][Full Text] [Related]
18. Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Programs.
Lee K; Jani T; Cheng R; Hunt J
Healthc Q; 2020 Apr; 23(1):10-12. PubMed ID: 32249733
[TBL] [Abstract][Full Text] [Related]
19. A pilot study on cost-related medication nonadherence in Ontario.
Zheng B; Poulose A; Fulford M; Holbrook A
J Popul Ther Clin Pharmacol; 2012; 19(2):e239-47. PubMed ID: 22805096
[TBL] [Abstract][Full Text] [Related]
20. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs.
Kang SY; Sen A; Bai G; Anderson GF
JAMA; 2019 Aug; 322(5):422-429. PubMed ID: 31386135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
